Acute Decompensated Heart Failure — ED Management

Key Points

• Classify acute heart failure by congestion and perfusion rather than assuming all patients need the same treatment.
• Prompt IV loop diuresis is recommended for patients admitted with significant fluid overload.
• Noninvasive positive-pressure ventilation is an important early therapy for cardiogenic pulmonary edema with respiratory distress.
• IV nitroglycerin or nitroprusside can be added in decompensated heart failure without systemic hypotension, particularly when severe afterload elevation contributes to dyspnea.
• Do not interpret a mild creatinine rise during successful decongestion as an automatic reason to stop diuresis.
• Persistent congestion should prompt a higher loop dose or addition of a second diuretic rather than repeated ineffective dosing.
• Cardiogenic shock is a different phenotype that requires perfusion support, urgent cause identification, and consideration of mechanical circulatory support.
• Chronic guideline-directed therapy should be continued or re-established whenever clinically feasible and optimized before discharge.

Algorithm

1. Assess airway, oxygenation, respiratory effort, blood pressure, perfusion, mental status, and signs of shock.
2. Determine whether the patient is congested and whether tissue perfusion is adequate.
3. Use ECG, chest imaging, laboratory testing, and bedside ultrasound to confirm the syndrome and identify precipitants.
4. For hypoxemic respiratory distress, provide oxygen and early noninvasive positive-pressure ventilation when appropriate.
5. For significant congestion, give an adequate IV loop diuretic dose and reassess urine output and symptoms within hours.
6. If diuresis is inadequate, increase the loop dose or add a second-site diuretic with close electrolyte monitoring.
7. For marked hypertension with pulmonary edema and no hypotension, add rapidly titratable IV vasodilation.
8. If shock or low-output hypoperfusion is present, prioritize perfusion support and urgent cardiology or shock-team evaluation.
9. Treat the precipitant, including ACS, arrhythmia, infection, hypertensive crisis, medication interruption, or mechanical cardiac disease.
10. Before discharge, establish euvolemia or a clear trajectory, optimize chronic therapy, provide a diuretic adjustment plan, and arrange early follow-up.

Clinical Synopsis & Reasoning

Acute decompensated heart failure is not a single hemodynamic state. Patients may present with pulmonary edema and severe hypertension, gradually progressive systemic congestion, right-sided failure, low-output cardiogenic shock, or a combination of these patterns. The initial bedside framework asks two questions: is the patient congested, and is tissue perfusion adequate? Congested patients are often described as wet, while patients with poor perfusion are cold. Most hospitalized patients are wet and warm, whereas a cold profile raises concern for advanced low-output physiology and requires more cautious use of vasodilators and diuretics.

Symptoms include dyspnea, orthopnea, paroxysmal nocturnal dyspnea, edema, abdominal distension, fatigue, early satiety, and reduced exercise tolerance. Examination should assess work of breathing, oxygen saturation, jugular venous pressure, lung findings, peripheral edema, perfusion, mentation, temperature, and blood pressure. Pulmonary crackles can be absent even with elevated filling pressures, and peripheral edema is not specific for heart failure. Point-of-care ultrasound can support the diagnosis by demonstrating B-lines, pleural effusions, reduced or preserved ventricular function, right ventricular dilation, and a plethoric inferior vena cava, but findings must be integrated with the clinical picture.

The diagnostic workup should also identify the precipitant. Common triggers include acute coronary syndrome, uncontrolled hypertension, atrial fibrillation or other arrhythmia, infection, medication nonadherence, excess sodium intake, renal dysfunction, anemia, thyroid disease, pulmonary embolism, myocardial or valvular disease, and medications that promote sodium retention or depress myocardial function. Natriuretic peptides are most useful when the diagnosis is uncertain; obesity can lower concentrations and kidney disease or atrial fibrillation can raise them. Troponin elevation is common in acute heart failure and does not automatically indicate type 1 myocardial infarction, but ischemia must be evaluated when symptoms or ECG findings support it.

Treatment Strategy & Disposition

Respiratory stabilization comes first. Give supplemental oxygen for hypoxemia rather than routinely to every patient. Noninvasive positive-pressure ventilation is highly useful in acute cardiogenic pulmonary edema with increased work of breathing because it improves oxygenation and reduces preload and afterload. Intubation is reserved for refractory hypoxemia, worsening fatigue, inability to protect the airway, severe encephalopathy, or shock that cannot be supported noninvasively.

Patients admitted with significant fluid overload should receive prompt IV loop diuretics. A diuretic-naive patient commonly receives an initial IV furosemide-equivalent dose sufficient to produce brisk natriuresis, while a patient already taking a loop diuretic generally requires an IV dose at least equivalent to and often greater than the home total daily dose. Reassess urine output, weight, symptoms, renal function, and electrolytes early rather than waiting until the next day to discover an inadequate response. If congestion persists despite an adequate loop dose, increase the loop dose or add sequential nephron blockade, such as a thiazide-type diuretic, with close electrolyte surveillance. A mild, transient creatinine rise during effective decongestion does not by itself require stopping diuresis.

For patients with decompensated heart failure who are not hypotensive, IV nitroglycerin or nitroprusside may be considered as an adjunct to diuretic therapy for dyspnea. Vasodilators are especially useful in hypertensive pulmonary edema, where rapid afterload reduction can produce major symptomatic improvement. In cardiogenic shock, avoid reflex vasodilation and use vasoactive support to maintain perfusion while rapidly identifying reversible causes and considering mechanical circulatory support. Routine morphine is not recommended as a heart-failure treatment because it can worsen respiratory and hemodynamic instability.

Chronic heart-failure medications should not be indiscriminately stopped. Preexisting guideline-directed medical therapy should generally be continued unless contraindicated by shock, severe hypotension, hyperkalemia, acute kidney injury that requires adjustment, or another specific problem. Once clinically stable, optimize HFrEF therapy before discharge, including the four foundational medication classes when appropriate. Disposition depends on oxygen need, hemodynamics, kidney function, diuretic response, arrhythmia, ischemia, and social reliability. Shock, escalating respiratory support, severe electrolyte disturbance, or need for continuous vasoactive therapy warrants intensive care.

Epidemiology / Risk Factors

• Heart failure is a leading cause of hospitalization among older adults and frequently recurs after discharge.
• Common precipitants include dietary or medication nonadherence, infection, ischemia, arrhythmia, uncontrolled hypertension, and kidney dysfunction.
• Patients with either reduced or preserved ejection fraction can develop acute congestion and pulmonary edema.
• Chronic kidney disease complicates diagnosis and diuretic treatment and increases readmission risk.
• Hypertensive acute heart failure often has rapid symptom onset driven by fluid redistribution and afterload, not solely by large total-body fluid gain.
• Residual congestion at discharge is a major marker of poor short-term outcome.

Investigations

Common Interventions

Pharmacology

Prognosis / Complications

• Short-term risk is highest with cardiogenic shock, persistent hypoperfusion, worsening respiratory failure, severe kidney dysfunction, and major precipitating events such as myocardial infarction.
• Successful decongestion and correction of the precipitant improve symptoms, but recurrent hospitalization remains common.
• Persistent congestion at discharge predicts early readmission and mortality.
• Patients with HFrEF benefit from early initiation and optimization of evidence-based disease-modifying therapy once stable.
• A transient creatinine rise during decongestion can occur without implying structural kidney injury, but progressive renal failure with poor perfusion requires reassessment.
• Early post-discharge follow-up and a clear diuretic plan reduce the chance that recurrent fluid retention will progress unnoticed.

Patient Education / Counseling

• Teach daily weight monitoring and explain what degree of rapid gain should trigger contact with the heart-failure team according to the individualized plan.
• Review sodium intake, medication adherence, and the specific role of the loop diuretic.
• Provide a written action plan for increasing edema, dyspnea, orthopnea, or reduced exercise tolerance.
• Advise urgent evaluation for severe breathlessness at rest, chest pain, syncope, confusion, or rapidly worsening edema.
• Review medications that can worsen heart failure, including many NSAIDs and selected diabetes or antiarrhythmic therapies when relevant.
• Explain that guideline-directed medications improve long-term outcomes even when the patient feels well and should not be stopped without guidance.
• Arrange early outpatient reassessment of weight, symptoms, kidney function, electrolytes, and medication tolerance after hospitalization.

Notes

The emergency goal is not simply to remove fluid. It is to restore effective gas exchange, reduce pathologic filling pressures, maintain organ perfusion, and identify the event that destabilized the patient. A hypertensive patient with flash pulmonary edema and a patient with cold cardiogenic shock may both carry the label acute heart failure but require very different first-hour management.

The 2022 AHA/ACC/HFSA heart-failure guideline recommends prompt IV loop diuretics for hospitalized patients with significant fluid overload and escalation to a higher loop dose or addition of a second diuretic when decongestion is inadequate. It also allows IV nitroglycerin or nitroprusside as an adjunct to diuretics for dyspnea in decompensated patients without systemic hypotension. Existing guideline-directed therapy should generally be continued unless a specific contraindication develops.

A successful discharge plan includes more than symptom improvement. The patient should have a stable respiratory and hemodynamic profile, a realistic diuretic regimen, medication reconciliation, a plan for laboratory surveillance, education about recurrent congestion, and timely follow-up. In HFrEF, hospitalization is an opportunity to initiate or optimize disease-modifying therapy once clinical stability is achieved.

References

1. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure — Link